诺和诺德（NVO）股价与投研分析
Novo Nordisk · 美国市场 · 医药健康
关键指标
- 最新价
- USD 42.18
- 日内涨跌
- +4.95%
- 市值
- USD 1859.82 亿
- 市盈率 TTM
- 10.31
- 市净率
- 5.68
- 52 周最高
- USD 64.16
- 52 周最低
- USD 35.12
- 股息率
- 4.26%
- 成交量
- 股 2603.83 万
- 上市市场
- 美国
公司概况
诺和诺德（英文名 Novo Nordisk，股票代码 NVO）在美国市场上市， 属于医药健康行业，当前处于成长阶段。核心标签：减肥药、GLP-1、胰岛素、丹麦。
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
AI 三层投研框架
- 宏观周期层：利率、通胀、汇率与流动性如何影响美国市场的估值中枢。
- 行业格局层：用 PEST、波特五力与产业链位置判断医药健康行业的利润分配。
- 公司质地层：把 诺和诺德 的增速、利润率、ROE 与现金流放进同行业横向对比。
需要完整报告？回到终端 可基于真实财报数据生成三层 AI 分析。